MiRXES
ABOUT
MiRXES is a Singapore-headquartered biotechnology company that translates research discoveries to deliver clinical diagnoses. MiRXES specializes in the development and delivery of microRNA-centric technology and services for a wide range of discovery and diagnostic applications.
Stories by MiRXES
Facing The Double Threat With Fortitude
By differentiating between the two diseases, MiRXES’ new Fortitude SARS-CoV-2 and flu A/B test could help countries face the ‘twindemic’ of flu and COVID-19.
Profiling A Panorama Of Pathologies
By targeting nearly 400 miRNAs linked to over 20 different diseases with a single product, MiRXES’ ID3EAL PanoramiR microRNA knowledge panel proves that it’s possible to achieve more with less.
Facing The Double Threat With Fortitude
By differentiating between the two diseases, MiRXES’ new Fortitude SARS-CoV-2 and flu A/B test could help countries face the ‘twindemic’ of flu and COVID-19.
Profiling A Panorama Of Pathologies
By targeting nearly 400 miRNAs linked to over 20 different diseases with a single product, MiRXES’ ID3EAL PanoramiR microRNA knowledge panel proves that it’s possible to achieve more with less.